S Rieg1, I Joost2, V Weiß3, G Peyerl-Hoffmann2, C Schneider4, M Hellmich5, H Seifert6, W V Kern2, A Kaasch7. 1. Division of Infectious Diseases, Department of Medicine II, University Medical Center Freiburg, Freiburg, Germany. Electronic address: siegbert.rieg@uniklinik-freiburg.de. 2. Division of Infectious Diseases, Department of Medicine II, University Medical Center Freiburg, Freiburg, Germany. 3. Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany. 4. Department of Medical Microbiology, University Medical Center Freiburg, Freiburg, Germany. 5. Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany. 6. Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany; German Centre for Infection Research (DZIF), Partner Site Cologne/Bonn, Germany. 7. Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany.
Abstract
OBJECTIVES: The evidence for using combination antimicrobial therapy (CoRx) in Staphylococcus aureus bacteraemia (SAB) is limited. We aimed to investigate whether CoRx is associated with higher survival or lower SAB-related late complications. METHODS: We performed a post hoc analysis of a prospective SAB cohort study. CoRx was defined as a cell wall-active antistaphylococcal agent plus either rifampicin, a fluoroquinolone, fosfomycin or an aminoglycoside. To adjust for survivor bias multivariable Cox models that included CoRx as a time-dependent covariable were calculated. RESULTS: Of 964 evaluable patients, 512 (53%) received CoRx, most of them (301/512, 59%) rifampicin-containing CoRx. All-cause mortality after 30 and 90 days was similar for the two groups, although the patients in the CoRx group had more often endocarditis, deep-seated or disseminated infections and severe sepsis/septic shock. For the entire cohort, only age, comorbidity and severe sepsis/septic shock were associated with a higher mortality and infectious disease consultation, but not CoRx with a lower mortality. However, in the subgroup of patients with implanted foreign bodies or devices CoRx was independently associated with a lower mortality at 30 days (hazard ratio 0.6, 95% confidence interval 0.3-1.1) and at 90 days (hazard ratio 0.6, 95% confidence interval 0.4-0.9). SAB-related late complications in this subgroup occurred in 15 (10.6%) of 142 patients in the monotherapy group vs. nine (4.5%) of 202 patients in the CoRx group (p 0.03). CONCLUSIONS: In a setting of optimized management of adult patients with SAB secured by infectious disease consultations, this observational study could not prove CoRx to be independently associated with improved survival or reduced late complications in the entire cohort. However, administration of CoRx may be associated with lower mortality and fewer SAB-related late complications in the subgroup of patients with implanted foreign bodies or devices. Prospective randomized trials should be performed to prove this benefit.
OBJECTIVES: The evidence for using combination antimicrobial therapy (CoRx) in Staphylococcus aureus bacteraemia (SAB) is limited. We aimed to investigate whether CoRx is associated with higher survival or lower SAB-related late complications. METHODS: We performed a post hoc analysis of a prospective SAB cohort study. CoRx was defined as a cell wall-active antistaphylococcal agent plus either rifampicin, a fluoroquinolone, fosfomycin or an aminoglycoside. To adjust for survivor bias multivariable Cox models that included CoRx as a time-dependent covariable were calculated. RESULTS: Of 964 evaluable patients, 512 (53%) received CoRx, most of them (301/512, 59%) rifampicin-containing CoRx. All-cause mortality after 30 and 90 days was similar for the two groups, although the patients in the CoRx group had more often endocarditis, deep-seated or disseminated infections and severe sepsis/septic shock. For the entire cohort, only age, comorbidity and severe sepsis/septic shock were associated with a higher mortality and infectious disease consultation, but not CoRx with a lower mortality. However, in the subgroup of patients with implanted foreign bodies or devices CoRx was independently associated with a lower mortality at 30 days (hazard ratio 0.6, 95% confidence interval 0.3-1.1) and at 90 days (hazard ratio 0.6, 95% confidence interval 0.4-0.9). SAB-related late complications in this subgroup occurred in 15 (10.6%) of 142 patients in the monotherapy group vs. nine (4.5%) of 202 patients in the CoRx group (p 0.03). CONCLUSIONS: In a setting of optimized management of adult patients with SAB secured by infectious disease consultations, this observational study could not prove CoRx to be independently associated with improved survival or reduced late complications in the entire cohort. However, administration of CoRx may be associated with lower mortality and fewer SAB-related late complications in the subgroup of patients with implanted foreign bodies or devices. Prospective randomized trials should be performed to prove this benefit.
Authors: D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern Journal: Anaesthesist Date: 2019-10 Impact factor: 1.041
Authors: Thomas L Holland; Issam Raad; Helen W Boucher; Deverick J Anderson; Sara E Cosgrove; P Suzanne Aycock; John W Baddley; Anne-Marie Chaftari; Shein-Chung Chow; Vivian H Chu; Manuela Carugati; Paul Cook; G Ralph Corey; Anna Lisa Crowley; Jennifer Daly; Jiezhun Gu; Ray Hachem; James Horton; Timothy C Jenkins; Donald Levine; Jose M Miro; Juan M Pericas; Paul Riska; Zachary Rubin; Mark E Rupp; John Schrank; Matthew Sims; Dannah Wray; Marcus Zervos; Vance G Fowler Journal: JAMA Date: 2018-09-25 Impact factor: 56.272
Authors: Achim J Kaasch; Winfried V Kern; Insa Joost; Martin Hellmich; Harald Seifert; Siegbert Rieg Journal: Open Forum Infect Dis Date: 2019-04-15 Impact factor: 3.835
Authors: Guy E Thwaites; Matthew Scarborough; Alexander Szubert; Emmanuel Nsutebu; Robert Tilley; Julia Greig; Sarah A Wyllie; Peter Wilson; Cressida Auckland; Janet Cairns; Denise Ward; Pankaj Lal; Achyut Guleri; Neil Jenkins; Julian Sutton; Martin Wiselka; Gonzalez-Ruiz Armando; Clive Graham; Paul R Chadwick; Gavin Barlow; N Claire Gordon; Bernadette Young; Sarah Meisner; Paul McWhinney; David A Price; David Harvey; Deepa Nayar; Dakshika Jeyaratnam; Tim Planche; Jane Minton; Fleur Hudson; Susan Hopkins; John Williams; M Estee Török; Martin J Llewelyn; Jonathan D Edgeworth; A Sarah Walker Journal: Lancet Date: 2017-12-14 Impact factor: 79.321
Authors: Yau Kei Stefan Leung; Bruno Ledergerber; Nadia Eberhard; Carlos A Mestres; Zoran Rancic; Alexander Zimmermann; Reinhard Zbinden; Silvio D Brugger; Annelies S Zinkernagel; Barbara Hasse Journal: JAC Antimicrob Resist Date: 2021-03-25